ReviewEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2024
Chromobacterium violaceum infections in children: two case reports and literature review.
Review in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An uncommon case of Chromobacterium violaceum urinary tract infection in a tertiary hospital in Ghana: a case report.Journal of medical case reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeChromobacterium violaceum(C. violaceum) is a gram-negative bacterium that rarely infects humans, especially children. However, the mortality rate is high and there are no clear guidelines for treatment. The aim of this paper is to increase clinicians' awareness of diseases caused by C. violaceum infections in children, to diagnose and treat them in a timely manner, to improve patient survival and to reduce mortality.
resultsWe analysed the latest paediatric-related English language literature over the last 10 years and summarised the latest mechanisms of injury, susceptibility factors, adverse prognostic and mortality predictors, mortality rates, methods to reduce mortality, clinical manifestations, new diagnostic methods, therapeutic agents and directions for future drug development for C. violaceum.
conclusionsBased on the available data, we conclude that the possibility of C. violaceum infection should be considered and diagnosed when cellulitis, septicaemia and visceral abscesses develop in children with a history of skin injury and exposure to stagnant water or soil. When clinicians strongly suspect that a child is infected with this bacterium, the recommended medication is ciprofloxacin if the child presents with severe illness. If the child has a non-severe condition, medications with relatively fewer side effects for children can be chosen, such as gentamicin, trimethoprim/ sulfamethoxazole, imipenem, and other drugs. The physician can then adjust the antimicrobial regimen based on the antimicrobial spectrum after obtaining the drug sensitivity results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.